New drug trial aims to stop dangerous bleeding in rare blood disorder
NCT ID NCT06211634
Summary
This early-stage clinical trial is testing a new drug called HMB-001 in adults with Glanzmann thrombasthenia, a rare inherited bleeding disorder. The main goals are to find a safe dose and see if regular injections can prevent or reduce the number and severity of bleeding episodes. The study involves 57 participants and will test single and multiple doses over several months to gather initial safety and effectiveness data.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLANZMANN THROMBASTHENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AP-HM - Hopital de la Timone
Marseille, France
-
AP-HP Hopital Bicetre (Part B/C)
Le Kremlin-Bicêtre, France
-
AP-HP Hopital Necker-Enfants Malades (Part B/C)
Paris, France
-
Azienda Ospedaliero-Universitaria Careggi (Part B/C)
Florence, Italy
-
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano (Part B/C)
Milan, Italy
-
Hemophilia Center of Western Pennsylvania (HCWP) (Part B/C)
Pittsburgh, Pennsylvania, 15213, United States
-
Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom
-
Mayo Clinic - Rochester (Part B/C)
Rochester, Minnesota, 55905, United States
-
Queen Elizabeth Hospital Birmingham (Part B/C)
Birmingham, United Kingdom
-
Richmond Pharmacology Ltd (Part A/B/C)
London, United Kingdom
-
Royal Free London NHS Foundation Trust (Part B/C)
London, United Kingdom
-
The Royal London Hospital (Part B/C)
Whitechapel, United Kingdom
-
Tulane University Medical Center (Part B/C)
New Orleans, Louisiana, 70112, United States
-
Universitair Medisch Centrum Utrecht (Part B/C)
Utrecht, Netherlands
-
University Hospital Leuven - Campus Gasthuisberg (Part B/C)
Leuven, Belgium
-
University of California, San Diego (UCSD) (Part B/C)
La Jolla, California, 92093, United States
-
Washington Institute for Coagulation (Part B/C)
Seattle, Washington, 98101, United States
Conditions
Explore the condition pages connected to this study.